ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia.
about
ACAT2 and human hepatic cholesterol metabolism: identification of important gender-related differences in normolipidemic, non-obese Chinese patientsACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity.Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.Seeking a unique lipid signature predicting cardiovascular disease risk.Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion.Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases.Multiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1.Discontinued drugs in 2005: cardiovascular drugs.The effects of sterol structure upon sterol esterificationDeletion of sterol O-acyltransferase 2 (SOAT2) function in mice deficient in lysosomal acid lipase (LAL) dramatically reduces esterified cholesterol sequestration in the small intestine and liver.Triterpenic Acids Present in Hawthorn Lower Plasma Cholesterol by Inhibiting Intestinal ACAT Activity in Hamsters.Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in miceThe association of cholesterol absorption gene Numb polymorphism with Coronary Artery Disease among Han Chinese and Uighur Chinese in Xinjiang, China.PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient miceCholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.Separation of cellular nonpolar neutral lipids by normal-phase chromatography and analysis by electrospray ionization mass spectrometryIdentification of putative active site residues of ACAT enzymesExploring the natural history of atherosclerosis with intravascular ultrasound.Identification of candidate genes encoding an LDL-C QTL in baboonsDevelopmental cigarette smoke exposure: liver proteome profile alterations in low birth weight pups.Localization of multiple pleiotropic genes for lipoprotein metabolism in baboons.Acyl-coenzyme A:cholesterol acyltransferases.Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2Sterol O-Acyltransferase 2-Driven Cholesterol Esterification Opposes Liver X Receptor-Stimulated Fecal Neutral Sterol Loss.Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.Atherosclerosis imaging in drug development.Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol lossIdentification of the interaction site within acyl-CoA:cholesterol acyltransferase 2 for the isoform-specific inhibitor pyripyropene ANonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation.Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver disease: is there a role for dietary coenzyme Q?Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats.Impact of loss of SOAT2 function on disease progression in the lysosomal acid lipase-deficient mouse.N-(3-Benzoylphenyl)-1H-Indole-2-Carboxamide decreases triglyceride levels by downregulation of Apoc3 gene expression in acute hyperlipidemic rat model.Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid.
P2860
Q24649651-EDFDBF5E-BF79-4549-BCD5-9E95461D6985Q30538414-0792395E-6B15-4945-A4EF-7F58D2DB8F7CQ33380457-015322D0-F563-4613-A80C-51AB4FFE4C69Q33600581-9E10379D-25F1-4A54-8892-CC2634BE8833Q33717139-B7175F56-5D89-4FAE-8E66-42A7BF5947FBQ34162283-0806F85A-D61E-4B3F-86E1-F2E291D301B2Q34357426-91034677-EABF-435D-BFD4-FE2282D277F9Q34573783-A44B6217-6DA0-49E1-8CB3-E74F750A5B0AQ34994931-21A46E8D-4F1B-4070-88A0-885628AA298EQ35032581-140C2C1D-1212-46A5-91A5-31829B93AAE3Q35116620-4D8D3038-0899-4D64-8D0D-78E79B1320D4Q35138400-0AB6B7DF-8E82-456F-A21F-E84B980B23E0Q36105172-C9033C1F-F209-4286-AA28-BAA070B43576Q36186220-232FE692-415A-4683-88A7-4FF33124206AQ36623056-674BAC00-D1A0-4DDB-ADB6-8A781B7EA297Q36631783-163F9E03-5AF0-4F41-B886-DE681EDD5C74Q36745055-1F671130-B366-4EF7-83D6-0D6DF029273DQ36752108-4BCD7189-0860-4DB1-A31D-3F85962643CFQ36920553-5524A36E-62D6-4799-997D-BAB9B0542DBCQ36975922-0AED36A2-04E1-4C9D-832D-2FE6652A6708Q37222418-D3EF6436-D704-41B9-8FF2-1670D6242C32Q37264194-6C6C413B-DBB4-4843-AEBE-0436A72A9FC2Q37377173-7415B69D-8D0F-40A7-837E-0D83F6A966B4Q37573558-30D2D6DB-1F01-4CAE-B0E9-5DB4DD84E8E8Q37705810-9B802CC7-947F-4B9D-AB49-A1A04909F504Q38504670-CC951DFC-004F-426B-95F5-1C4AF98F456BQ39782322-C6C94E8E-B0D1-408E-B239-92D3089B7C01Q39782773-2017C700-D862-4150-AAB2-3BFAE621389BQ42806308-092C4C76-6177-45AA-AC73-020D46175F21Q45927414-94CD6E0E-CB24-4993-8301-01CB4BBF9A30Q47110162-ED899406-98BE-4D70-8DCD-5BA60A0E29E2Q47300957-6C4439CE-1E37-400D-83FF-A7D7335F6538Q51113879-AFD0BF10-77F0-4309-8EF1-D424472B7CBDQ51802068-F8D71245-D271-4B5F-85A2-6411CDCC70CF
P2860
ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
ACAT2 is a target for treatmen ...... ted with hypercholesterolemia.
@ast
ACAT2 is a target for treatmen ...... ted with hypercholesterolemia.
@en
type
label
ACAT2 is a target for treatmen ...... ted with hypercholesterolemia.
@ast
ACAT2 is a target for treatmen ...... ted with hypercholesterolemia.
@en
prefLabel
ACAT2 is a target for treatmen ...... ted with hypercholesterolemia.
@ast
ACAT2 is a target for treatmen ...... ted with hypercholesterolemia.
@en
P2093
P1476
ACAT2 is a target for treatmen ...... ted with hypercholesterolemia.
@en
P2093
Lawrence L Rudel
Paolo Parini
Richard G Lee
P304
P356
10.1161/01.ATV.0000166548.65753.1E
P577
2005-04-14T00:00:00Z